SCHEMBL31460101

SCHEMBL31460101

CCOC(=O)c1c(NC(C)=O)sc2c(O)c(Cl)cc(Cl)c12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.68
▸ MAPT P10636 5/20 0.68
▸ KMT2A Q03164 5/20 0.68
▸ MEN1 O00255 4/20 0.68
▸ MCL1 Q07820 1/20 0.68
▸ LMNA P02545 1/20 0.58
▸ ALOX12 P18054 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ KDM4E B2RXH2 3/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ TSHR P16473 3/20 0.51
▸ PRKCZ Q05513 1/20 0.50
▸ RECQL P46063 1/20 0.48
▸ HPGD P15428 3/20 0.43
▸ TP53 P04637 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31459976 0.81 MAPT (0.75) ALDH1A1MAPTKMT2AMEN1MCL1
SCHEMBL31460105 0.80 MAPT (0.53) ALDH1A1MAPTKMT2AMEN1MCL1
SCHEMBL31459968 0.73 MAPT (1.00) ALDH1A1MAPTKMT2AMEN1MCL1
SCHEMBL2921771 0.73 MAPT (1.00) ALDH1A1MAPTKMT2AMEN1MCL1
SCHEMBL3988992 0.72 MAPT (0.67) ALDH1A1MAPTKMT2AMEN1MCL1
SCHEMBL31459864 0.71 KMT2A (1.00) ALDH1A1MAPTKMT2AMEN1MCL1
SCHEMBL15172955 0.71 KMT2A (1.00) ALDH1A1MAPTKMT2AMEN1MCL1
SCHEMBL3982203 0.71 MAPT (0.64) ALDH1A1MAPTKMT2AMEN1MCL1
SCHEMBL13886692 0.71 MAPT (0.60) ALDH1A1MAPTKMT2AMEN1MCL1
SCHEMBL16521105 0.71 MAPT (0.78) ALDH1A1MAPTKMT2AMEN1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors ENANTA PHARMACEUTICALS, INC. 2025-05-15 — — US disclosed
WO-2025090868-A1 PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2025-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors HSD17B13, HSD17B1, HSD11B1 ALDH1A1 106/4885MAPT 3628/4885KMT2A 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback